Entasis Therapeutics Holdings Inc ETTX Fundamentals and Key Ratios

Entasis Therapeutics Holdings Inc. (ETTX) Fundamentals


Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).

Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).

SHARE INFORMATION
Market Cap	$ 104,795,396
Shares Outstanding	47,851,779
Float	18,613,976
Percent Float	38.9%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 0
Latest Fiscal EPS	$ -1.09
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	67
Institutional Holdings Date	2022-06-30
Institutional Bought Previous 3 Months	122,646
Institutional Holdings Percent	10.8%
Institutional Sold Previous 3 Months	435,111
Insider Holdings Date	2022-06-30
Insider Bought Previous 3 Months	-
Insider Holdings Percent	4.1
Insider Sold Previous 3 Months	-
Insider Shares Owned	1,965,048

TRADING INFO
52 Week High	$ 3.88
52 Week Low	$ 1.40
52 Week High Change	$ -19.19
21 Day Moving Average	$ 2.19
21 Day Extended Moving Average	$ 2.1897
50 Day Moving Average	$ 2.1904
50 Day Extended Moving Average	$ 2.1735
200 Day Moving Average	$ 2.0364
200 Day Extended Moving Average	$ 2.1674
10 Day Average Volume	-
20 Day Average Volume	-
30 Day Average Volume	27
50 Day Average Volume	10,131
Alpha	-0.024932
Beta	1.2388
Standard Deviation	0.182351
R2	0.142766
7 Day Price Change	$ 0.00
7 Day Percent Change	0.0%
21 Day Price Change	$ 0.00
21 Day Percent Change	0.0%
30 Day Price Change	$ 0.00
30 Day Percent Change	0.0%
Month to Date Price Change	$ 0.00
Month to Date Percent Change	0.0%
Quarter to Date Price Change	$ -0.01
Quarter to Date Percent Change	-0.45%
180 Day Price Change	$ 0.54
180 Day Percent Change	32.73%
200 Day Price Change	$ 0.38
200 Day Percent Change	20.99%
Year to Date Price Change	$ 0.00
Year to Date Percent Change	0.0%

PROFITABILITY
EBIT Margin	-662.4%
EBITDA Margin	-660.4%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	0.0%
Gross Margin	0.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 0
Revenue Per Share	$ 0.00
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	6.30
Total Debt To Equity	1.10
Int Coverage	-5,169.20
Current Ratio	1.70
Leverage Ratio	1.80
Quick Ratio	1.40
Long Term Debt To Capital	0.17

VALUATION MEASURES
PE Ratio	-2.00
Enterprise Value	$ 90,102,396
Price to Sales	0.00
Price to Free Cash	-2.70
PE High Last 5 Years	0.00
Price To Book	6.30
Price To Cash Flow	0.00
PE Low Last 5 Years	0.00
Price to Tangible Book	6.30

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.00
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-106.70
Return on Equity	-169.78
Return on Capital	-127.80

PROFILE INFO
Issue Type	CS
SEC Type	-
Auditor	KPMG LLP
CEO	Manoussos Perros
Emplyoees	51
Last Audit	UE
CIK	0001724344
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	35 Gatehouse Drive Waltham, MA 2451
Website	https://www.entasistx.com
Facsimile	-
Telephone	+1 781 810-0120
Email	kyle.dow@entasistx.com

Boards:

Quotes:

ETTX